SESOTHO: "Switch Either Near Suppression Or THOusand"
Study Details
Study Description
Brief Summary
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL. However, the optimal threshold for defining virological failure and the need to switch ART regimen has not been determined. In fact, people with VL levels of less than 1000 copies/mL, however, not fully suppressed, are at increased risk for drug resistance mutations (DRM) and subsequent virological failure. In resource-limited settings where VL monitoring is not as frequent as in high-income countries, this could have serious implications and patients may continue on a failing regimen for a long period. Our research consortium will conduct a multicenter, parallel-group, open-label, randomized clinical trial in a resource-limited setting to assess whether a threshold of 100 copies/mL compared to the WHO-defined threshold of 1000 copies/mL for switching to second-line ART among unsuppressed HIV-positive patients on first-line ART will lead to better outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Study background & rational:
The Joint United Nations Programme on HIV/AIDS (UNAIDS) launched the 90-90-90 targets for 2020 based on the result of newly-acquired scientific evidence that - irrespective of CD4 count - early antiretroviral treatment (ART) for HIV-positive individuals is beneficial to them and prevents HIV transmission. UNAIDS expects that the 90-90-90 targets will lead to a reduction in the yearly global HIV incidence from 2 million currently to 500,000 by 2020.
A crucial step to achieve the third pillar of the UNAIDS 90-90-90 targets - 90% viral suppression among HIV-positive individuals on treatment - and thus ensure a successful treatment outcome is the monitoring and management of first-line ART failure.
Since 2013, the WHO recommends routine viral load (rVL) measurement as the preferred monitoring strategy in resource-limited settings and defines virological failure as confirmed VL 1000 copies/mL despite good adherence. Specifically, the guidelines recommend that in case of a VL ≥ 1000 copies/mL the patient should undergo enhanced adherence support and a second VL test 3 months later. A second VL ≥ 1000 copies/mL with confirmed good adherence would trigger the switch to a second-line regimen, whereas if the VL is < 1000 copies/mL the patient should continue unaltered first-line ART. However, the optimal threshold for defining virological failure and the need for switching ART regimen has not yet been determined. In fact, people with VL levels of less than 1000 copies/mL, but not fully suppressed (usually defined as 50-100 copies/mL), are at a increased risk for drug resistance mutations (DRM) and subsequent virological failure. A recently published study from our research consortium in Lesotho indicates similar findings, demonstrating a significant accumulation of drug resistance mutations in patients with VL levels of less than 1000 copies/mL.
The VL threshold of 1000 copies/mL recommended by the WHO and the Lesotho national guidelines for the switch to second-line ART is likely to miss a substantial number of patients on first-line ART with persisting virus replication below 1000 copies/mL with DRM. In resource-limited settings where VL monitoring is not as frequent as in high-income countries, this could have serious implications: after a VL below 1000 copies/mL the patient may not receive a follow-up VL for up to a year, and thus may continue on a failing regimen for a long period of time. In conclusion, such patients are at increased risk for DRM, accumulation of further resistance mutations, drug-resistant virus transmission, and subsequent virological failure.
Study hypothesis:
Our research consortium hypothesizes that in patients on first-line ART with two consecutive unsuppressed VL measurements equal/more than 100 copies/mL, where the second VL is between 100 and 999 copies/mL, switch to second-line ART (intervention group) will lead to a higher rate of viral resuppression (VL < 50 copies/mL) and is therefore superior compared to not switching to second-line ART according to WHO guidelines (control group, standard of care).
Study design:
Multicenter (2-12 centers), parallel-group (1:1 allocation), open-label, superiority, prospective randomized clinical study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention switch to second-line ART |
Other: switch
switch to second-line ART
|
| No Intervention: Control Standard of care: no switch to second-line ART |
Outcome Measures
Primary Outcome Measures
- viral suppression [9 months after randomization]
Proportion of virologically suppressed (VL < 50 copies/mL) participants 9 months after randomization.
Secondary Outcome Measures
- Proportion of participants with different VL thresholds (VL <100, <200, <400, <1000 copies/mL) at 9 months after randomization [9 months after randomization]
- Adherence at 3, 6, 9 months, assessed by self-reported dose omission [3, 6, 9 months after randomization]
- Change in values (versus values at baseline) of body-weight (kg) at 9 months [9 months after randomization]
- Change in values (versus values at baseline) of haemoglobin (g/dL) at 9 months [9 months after randomization]
- Change in values (versus values at baseline) of CD4 count (cells/mL) at 9 months [9 months after randomization]
- Change in values (versus values at baseline) of lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l) at 9 months [9 months after randomization]
- Change in values (versus values at baseline) of new clinical WHO 3 or 4 events (proportion) count at 9 months [9 months after randomization]
- Change in values (versus values at baseline) of deaths (all-causes) (proportion) at 9 months [9 months after randomization]
- Proportion of patients with adverse events and serious adverse events at 9 months after randomization [9 months after randomization]
- Long-term follow-up endpoint: Proportion of patients that are alive, retained in care and virologically suppressed (VL < 50 copies/mL) at 24 months [24 months after randomization]
- Proportion of virologically suppressed (VL < 50 copies/mL) participants by demographic groups (children vs pregnant women vs adults) [9 months after randomization]
- Proportion of virologically suppressed (VL < 50 copies/mL) participants by different VL groups at enrolment (VL 100-599 vs 600-999 copies/mL copies/mL) [9 months after randomization]
- Proportion of participants with viral resuppression (<50 copies/mL) [6 months after randomization]
- Sustained virologic failure [6 and 9 months after randomization]
Proportion of participants with unsuppressed VL >50 copies/mL at 6 and 9 months
Other Outcome Measures
- Direct costs of each treatment arm [9 months and 24 months after randomization]
- Prevalence of major viral resistance mutations to first-line regimen in each treatment arm for all samples for which an RT-PCR amplification is successful [9 months after randomization]
- pre-specified subgroup: Log-drop [9 months after randomization]
Viral resuppression among individuals with a >0.5 drop in log10 VL between the first screening VL and the second screening VL (i.e. VL at enrolment)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
On NNRTI-based first-line ART with two consecutive unsuppressed VL equal/more 100 copies/mL, with the second VL between 100 and 999 copies/mL.
-
Lives and/or works in the district of Butha-Buthe and declares to seek follow-up at one of the study-facilities
-
Signed written informed consent. For children aged <16 years, a main caregiver, and for illiterate a literate witness, has to provide oral and written informed consent.
Exclusion Criteria:
-
On ART less than 6 months
-
On protease-inhibitor containing ART or any other second-line ART
-
Bad adherence (self-reported at least 1 dose missing in the last 4 weeks, resp. 2 doses of a twice-daily-regimen)
-
Clinical WHO stage 3 or 4 at enrolment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Motebang Hospital, ART corner | Hlotse | Leribe | Lesotho | |
| 2 | Butha-Buthe Hospital | Butha-Buthe | Lesotho | 400 | |
| 3 | Seboche Hospital | Butha-Buthe | Lesotho | 400 | |
| 4 | Muela Health Center | Butha-Buthe | Lesotho | ||
| 5 | St. Paul Health Center | Butha-Buthe | Lesotho | ||
| 6 | St. Peters Health Center | Butha-Buthe | Lesotho | ||
| 7 | Senkatana ART clinic | Maseru | Lesotho | ||
| 8 | Mokhotlong Hospital | Mokhotlong | Lesotho |
Sponsors and Collaborators
- Niklaus Labhardt
- Swiss Tropical & Public Health Institute
- SolidarMed, Lucerne, Switzerland
- SolidarMed, Maseru, Lesotho
- University of Basel
- University Hospital, Basel, Switzerland
- Butha-Buthe Hospital, Lesotho
- Ministry of Health, Lesotho
Investigators
- Principal Investigator: Niklaus Labhardt, MD MIH, Swiss Tropical and Public Health Institute, Basel
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- P002-17-1.0